Farther Finance Advisors’s ProPhase Labs PRPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 6293 |
|
|
2026
Q2 | $1 | Hold |
10
| – | – | ﹤0.01% | 5973 |
|
|
2026
Q1 | $1 | Buy |
10
+1
| +11% | – | ﹤0.01% | 5747 |
|
|
2025
Q4 | $4 | Sell |
9
-1
| -10% | -$3 | ﹤0.01% | 5430 |
|
|
2025
Q3 | $44 | Hold |
10
| – | – | ﹤0.01% | 4876 |
|
|
2025
Q2 | $38 | Hold |
10
| – | – | ﹤0.01% | 4389 |
|
|
2025
Q1 | $39 | Hold |
10
| – | – | ﹤0.01% | 4146 |
|
|
2024
Q4 | $73 | Hold |
10
| – | – | ﹤0.01% | 3834 |
|
|
2024
Q3 | $235 | Hold |
10
| – | – | ﹤0.01% | 3613 |
|
|
2024
Q2 | $394 | Hold |
10
| – | – | ﹤0.01% | 3328 |
|
|
2024
Q1 | $664 | Hold |
10
| – | – | ﹤0.01% | 2929 |
|
|
2023
Q4 | $438 | Hold |
10
| – | – | ﹤0.01% | 3011 |
|
|
2023
Q3 | $424 | Hold |
10
| – | – | ﹤0.01% | 2312 |
|
|
2023
Q2 | $704 | Hold |
10
| – | – | ﹤0.01% | 2056 |
|
|
2023
Q1 | $739 | Hold |
10
| – | – | ﹤0.01% | 1910 |
|
|
2022
Q4 | $934 | Buy |
+10
| New | +$1.08K | ﹤0.01% | 1671 |
|
Farther Finance Advisors's PRPH Position: Q3 2026 in Review
Farther Finance Advisors held its ProPhase Labs (PRPH) position steady in Q3 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6293.
Farther Finance Advisors first reported a position in PRPH in Q4 2022 and has held it in 16 quarters since. The position peaked at $934 in Q4 2022. 2 funds tracked by Wall St. Rank hold PRPH as of Q3 2026.
- Farther Finance Advisors held 10 shares of ProPhase Labs worth $0 as of Q3 2026.
- Farther Finance Advisors left its ProPhase Labs share count unchanged in Q3 2026.
- ProPhase Labs made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #6293 holding.
- Farther Finance Advisors first reported a position in ProPhase Labs in Q4 2022 and has held it in 16 quarters since.
- Farther Finance Advisors's ProPhase Labs position peaked at $934 in Q4 2022.
- 2 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2026.
Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.